Latest Content

A marketing authorization application for lirafugratinib in previously treated FGFR2-altered metastatic cholangiocarcinoma has been submitted to the EMA.

Toon Van Gorp, MD, PhD, discusses NAPISTAR 1-01 trial design, safety findings, and efficacy across dose levels of TUB-040 in ovarian cancer.

A PET-guided, nivolumab-based regimen produced promising response rates in advanced-stage classical Hodgkin lymphoma.

Japan approved T-DXd plus pertuzumab for HER2-positive disease and Dato-DXd for triple-negative disease in first-line metastatic breast cancer.

The University of Texas MD Anderson Cancer Center and Springer Nature will co-host a conference to explore the latest research on cancer therapeutics.

Cesalatamig earned FDA fast track designation for NSCLC that progressed after immunotherapy and platinum-based chemotherapy.

Data from a retrospective study showed high levels of CEACAM1 expression in patients with mantle cell lymphoma.

The phase 2 AMIGO-1 trial met its end point, with an 18-month PFS rate of 66.7% for first-line amivantamab, lazertinib, and pemetrexed in EGFR-mutant NSCLC.

First-line osimertinib plus gefitinib produced an 82.1% response rate and blocked second-site EGFR resistance mutations, but missed feasibility criteria.

The FDA set a target action date of June 29, 2027, for bezuclastinib's NDA in advanced systemic mastocytosis, backed by APEX trial data.

The phase 3 ECHO trial confirmed a durable progression-free survival benefit with frontline acalabrutinib-based therapy in mantle cell lymphoma.

Obesity may increase breast cancer risk partly by removing a natural defense.

Daraxonrasib plus gemcitabine and nab-paclitaxel received FDA breakthrough therapy designation for treatment-naive metastatic pancreatic adenocarcinoma.

KST-6051 received FDA fast track designation for KRAS-mutant solid tumors.

Alexandra Leary, MD, PhD, discusses TEDOVA's design, the safety profile of OSE2101, and implications for maintenance in ovarian cancer.

ASCO's first living guideline backs platinum doublets and mirvetuximab soravtansine for FRα+, high-grade platinum-resistant ovarian cancer.

Osimertinib plus platinum-pemetrexed showed a numerical PFS and OS advantage over osimertinib alone regardless of baseline TP53 status in FLAURA2.

The FDA has approved lutetium Lu 177 dotatate injection for SSTR-positive GEP-NETs, including foregut, midgut, and hindgut NETs.

Strong overall response rates with pirtobrutinib in relapsed/refractory CLL previously treated with covalent BTK inhibitors were shown in a pooled analysis.

Real-world tumor lysis syndrome occurred in less patients with CLL who received venetoclax-based regimens than those with MCL.

Dana-Farber Cancer Institute is launching Solavia Decision Suite to bring clinical expertise and evidence-based treatment pathways directly into clinicians’ workflows.

The FDA indication for adagrasib plus cetuximab for KRAS G12C–mutated locally advanced or metastatic colorectal cancer has been removed.

The updated tarlatamab label reduces post-infusion monitoring after each of the first two doses to 6 to 8 hours, down from 22 to 24 hours.

TLX101-Px, an FET-PET imaging agent, was FDA approved to differentiate treatment-related changes from recurrent or progressive glioma.

The FDA approved aminolevulinic acid hydrochloride plus PDT for the treatment of superficial basal cell carcinoma.

TKI-based regimens were associated with higher rates of disease control in metastatic translocation renal cell carcinoma.

Jay M. Lee, MD, discusses how NAUTIKA1 compares with ALNEO and LORIN, why full genomic profiling is now essential before starting chemoimmunotherapy, and how tumor boards will manage early-stage NSCLC in 5 years.

Jay M. Lee, MD, discusses the primary analysis of the ALK+ cohort of NAUTIKA1, what MPR status adds to risk stratification, and whether neoadjuvant alectinib is ready for patients today.

David R. Gandara, MD, discusses why PD-L1 scoring in NSCLC undercounts immunotherapy benefit and where TMB and plasma proteomics fit alongside it.

The final OS analysis of PAPILLON did not reach statistical significance in the ITT population, but a pre-specified crossover-adjusted analysis showed a 43% reduction in the risk of death.

An exploratory landmark analysis of the phase 3 ADAURA trial showed 8-year OS rates of 79% versuss 64% with placebo, with benefit maintained across stages and subgroups.

Frontline zidesamtinib produced a 94% response rate and 100% intracranial response rate in TKI-naive ROS1-positive advanced NSCLC.

First-line trastuzumab deruxtecan reduced the risk of progression or death by 37% compared with pembrolizumab plus chemotherapy in HER2-mutant non–small cell lung cancer.

Edgardo S. Santos Castillero, MD, discusses MAVERICK, B7-H3 ADC data, and tarlatamab sequencing in SCLC, plus molecular testing in a value-based practice.

Adding intercalated gefitinib to adjuvant chemotherapy improved DFS vs chemotherapy alone in completely resected stage II-IIIB EGFR-mutant NSCLC in a phase 3 trial.

The top 5 OncLive TV videos of the week cover insights in polycythemia vera, myelodysplastic syndrome, myelofibrosis, and acute myeloid leukemia.

A real-world study found just one-third of patients remained on adjuvant osimertinib at 3 years, with early discontinuation linked to worse disease-free survival.

Primary results from the phase 3 ARTEMIS-008 trial presented at WCLC 2026 showed risvutatug rezetecan reduced the risk of death by 54% and more than doubled PFS.

Tambotatug pelitecan improved survival and confirmed ORR in the phase 3 TAISHAN-302 trial presented at WCLC 2026.

Randomized dose-expansion data from the global phase 1 study establish the recommended phase 3 dose for the EGFR x HER3 bispecific ADC in the IZABRIGHT-Lung01 trial.

Final analysis of the phase 3 IMpower030 trial showed a median EFS of 62.8 months versus 34.9 months with placebo plus chemotherapy in stage IIB to IIIB disease.

First data from the phase 1B/2 BNT324-01 trial pair a PD-L1 and VEGF-A bispecific antibody with a B7H3-directed ADC in patients with SCLC.

Every-3-week and every-4-week tarlatamab regimens produced ORRs of 31% and 27% vs 40% with standard bi-weekly dosing in the phase 2 DeLLphi-309 trial.